PTIXOTCPharmaceutical PreparationsFiscal year ends March 31

Protagenic Therapeutics, Inc.\new

Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026

$0.75+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $1.36M
P/E (TTM): –
Dividend yield: –

Protagenic Therapeutics, Inc.\new income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2014 2014-06-30	FY 2013 2013-06-30
Revenue	0	0	0	0	0	–	–	–	0	–	–
Research & Development	3.84	3.06	1.59	1.14	0.70	0.81	0.88	0.72	0.42	0.04	–
General & Administrative	1.76	1.21	1.97	3.00	1.85	1.28	1.43	1.65	1.41	–	–
Operating Expenses	5.70	4.53	3.56	4.14	2.55	2.09	2.31	2.37	2.23	–	–
Operating Income	-5.70	-4.53	-3.56	-4.14	-2.55	-2.09	-2.31	-2.37	-2.23	–	–
Interest Expense	–	0.11	0.14	0.50	0.25	–	–	–	0.01	0.00	–
Interest & Investment Income	0.04	0.26	0.19	0.03	0.00	–	–	–	–	–	–
Other Non-Operating Income	0.18	-0.47	0.00	-0.38	0.00	0.34	-0.24	0.11	-0.04	–	–
Asset Impairment Charges	–	–	–	–	–	–	–	–	0.40	–	–
Gain (Loss) on Investments	–	–	0.05	–	–	–	–	–	–	–	–
Pretax Income	-5.53	-5.00	-3.56	-4.52	-2.55	-1.75	-2.56	-2.26	-2.28	–	–
Income Tax Expense	–	–	–	–	–	–	–	–	0	0	0
Minority Interest in Earnings	–	–	–	–	–	–	–	–	–	-0.05	–
Net Income	-5.53	-5.00	-3.56	-4.52	-2.55	-1.75	-2.56	-2.26	-2.28	-1.08	–
EPS (Basic)(per share)	-15.82	-16.10	-11.48	-17.36	-14.00	-9.52	-14.00	-12.32	-24.08	–	–
EPS (Diluted)(per share)	-15.82	-16.10	-11.48	-17.36	-14.00	-9.52	-14.00	-12.32	-24.08	–	–
Shares Outstanding (Basic, Weighted)(shares)	0.35	0.31	0.31	0.26	0.18	0.18	0.18	0.18	0.09	–	–
Shares Outstanding (Diluted, Weighted)(shares)	0.35	0.31	0.31	0.26	0.18	0.18	0.18	0.18	0.09	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2024: -3157.4%

Financial strength

Current ratio: 0.66
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 52.8%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.79
Dividend yield: –